Esperion Therapeutics (ESPR) Revenue Growth (3y) (2022 - 2026)
Esperion Therapeutics (ESPR) Revenue Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 15.52% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 2.94% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 48.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.77% |
| Dec 31, 2025 | 107.63% |
| Sep 30, 2025 | 66.31% |
| Jun 30, 2025 | 63.52% |
| Mar 31, 2025 | 51.11% |
| Dec 31, 2024 | 64.94% |
| Sep 30, 2024 | 53.02% |
| Jun 30, 2024 | 22.00% |
| Mar 31, 2024 | 158.45% |
| Dec 31, 2023 | 49.57% |
| Sep 30, 2023 | 106.94% |
| Jun 30, 2023 | -50.47% |
| Mar 31, 2023 | 136.47% |
| Dec 31, 2022 | 167.60% |
| Sep 30, 2022 | 168.46% |
| Jun 30, 2022 | 167.71% |
| Mar 31, 2022 | -49.40% |